ArticleAAPS PharmSciTech2025
Palatable Orally Disintegrating Tablets of Losartan Potassium Developed by Spray-drying Technique and Direct Compression Intended for Pediatric Use.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Several diseases that affect the pediatric population, e.g., heart diseases, cannot be efficiently treated because of the absence of a suitable dosage form. In this sense, orally disintegrating tablets (ODT) are solid dosage forms that are gaining acceptance. Losartan potassium (LP) is the drug of choice for managing pediatric arterial hypertension, although its bitter taste represents a major challenge to treatment compliance. To mitigate this drawback, this study aimed to develop palatable ODT, by the incorporation of spray-dried powders (SDP), composed of LP, Eudragit® polymers and adjuvants (i.e., colloidal silicon dioxide, mannitol, and PEG4000). The SDP were analyzed in terms of production yield and encapsulation efficiency. Selected SDP were incorporated into ODT by direct compression, and characterized in terms of mechanical and pharmaceutical properties, as well as palatability. Tablets with satisfactory disintegration time, hardness, and friability were obtained, though different performance during in vitro dissolution study. In the palatability study, the volunteer panel confirmed that the ODT-7SDP formulation, prepared by spray drying with Eudragit® E PO and colloidal silicon dioxide, showed a marked reduction in LP bitterness. In conclusion, the applied technologies successfully reduced the bitter taste of LP, enabling its oral administration in the form of ODT, particularly for pediatric patients.
Indexed as
Identifiers
40804221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.